{'fraction_non_alphanumeric': 0.043209876543209874, 'fraction_numerical': 0.016975308641975308, 'mean_word_length': 4.453781512605042, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anti-tumour efficacy of IL-1 and IL-2.

The potential value of RIL-1 and RIL-2 for local immunotherapy of cancer was compared in the experimental model of MC-induced sarcomas growing in syngeneic (B10) mice. Highly purified recombinant human RIL-1 (Hoffmann-La Roche) and RIL-2 (Amersham) were administered s.c. into the area of lymph nodes draining the growing tumour. Within the dose range examined, RIL-2 was capable of inducing inhibition of tumour growth or complete regression of tumours and the cure of the majority of treated mice. In contrast, RIL-1 could neither inhibit tumour growth nor potentiate the tumour-inhibitory effect of RIL-2.